BG Medicine, Inc. to Present at Cowen and Company 33rd Annual Health Care
WALTHAM, Mass., Feb. 27, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc.
(Nasdaq:BGMD) ), a company focused on the development and commercialization of
novel cardiovascular diagnostics, announced today that Eric Bouvier, BG
Medicine's President and CEO, will be presenting at the Cowen and Company33rd
AnnualHealth Care Conference on March 4, 2013, at the Boston Marriott Copley
Place, beginning at 2:10 PM Eastern Time (ET).
Audio and slides of BG Medicine's presentation will be webcast at:
The webcast will be archived for 30 days following the live presentation on BG
Medicine's Investor Relations website at ir.BG-medicine.com.
About BG Medicine
BG Medicine, Inc. (Nasdaq:BGMD) is a diagnostics company focused on the
development and commercialization of novel cardiovascular tests to address
significant unmet medical needs, improve patient outcomes and reduce
healthcare costs. The Company has two products: the BGM Galectin-3® test for
use in patients with chronic heart failure is available in the United States
and Europe; and the CardioSCORE™ test for the risk prediction of major
cardiovascular events will be launched in Europe in the first half of 2013.
For additional information about BG Medicine, heart failure and galectin-3
testing, please visit www.bg-medicine.comand www.galectin-3.com.
The BG Medicine Inc. logo is available at
CONTACT: Chuck Abdalian
EVP & Chief Financial Officer
BG Medicine Inc. logo
Press spacebar to pause and continue. Press esc to stop.